NASDAQ:BCDA - Nasdaq - US09060U6064 - Common Stock - Currency: USD
2.85
0 (0%)
The current stock price of BCDA is 2.85 USD. In the past month the price increased by 47.67%. In the past year, price decreased by -52.01%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.97 | 326.55B | ||
AMGN | AMGEN INC | 12.81 | 142.94B | ||
GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
NTRA | NATERA INC | N/A | 20.66B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
BIIB | BIOGEN INC | 7.47 | 17.32B |
BioCardia, Inc. is a clinical-stage biotherapeutic company. The company is headquartered in Sunnyvale, California and currently employs 17 full-time employees. The company is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
BIOCARDIA INC
320 Soquel Way
Sunnyvale CALIFORNIA 94070 US
CEO: Peter Altman
Employees: 19
Phone: 16502260123
The current stock price of BCDA is 2.85 USD.
The exchange symbol of BIOCARDIA INC is BCDA and it is listed on the Nasdaq exchange.
BCDA stock is listed on the Nasdaq exchange.
8 analysts have analysed BCDA and the average price target is 15.81 USD. This implies a price increase of 454.74% is expected in the next year compared to the current price of 2.85. Check the BIOCARDIA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOCARDIA INC (BCDA) has a market capitalization of 13.34M USD. This makes BCDA a Nano Cap stock.
BIOCARDIA INC (BCDA) currently has 19 employees.
BIOCARDIA INC (BCDA) has a support level at 2.62 and a resistance level at 2.86. Check the full technical report for a detailed analysis of BCDA support and resistance levels.
The Revenue of BIOCARDIA INC (BCDA) is expected to decline by -84.28% in the next year. Check the estimates tab for more information on the BCDA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BCDA does not pay a dividend.
BIOCARDIA INC (BCDA) will report earnings on 2025-08-11.
BIOCARDIA INC (BCDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.25).
The outstanding short interest for BIOCARDIA INC (BCDA) is 1.1% of its float. Check the ownership tab for more information on the BCDA short interest.
ChartMill assigns a technical rating of 6 / 10 to BCDA. When comparing the yearly performance of all stocks, BCDA is a bad performer in the overall market: 75.19% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to BCDA. While BCDA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months BCDA reported a non-GAAP Earnings per Share(EPS) of -8.25. The EPS increased by 17.91% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -213.37% | ||
ROE | -949.34% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to BCDA. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 61.55% and a revenue growth -84.28% for BCDA